果糖二磷酸钠是心肌缺血辅助治疗药,临床上适用于多种心血管病的辅助治疗。由于其在临床上普遍采用大输液用药,故大输液中不溶性微粒的控制,将直接影响产品质量。不溶性微粒若进入人体后,将引起全身大器官的栓塞及过敏样和热原样反应,因此控制该品种中不溶性微粒是临床用药安全的关键。目前,在临床用药时要避免微粒直接进入人体,只有靠 Fructose diphosphate is an adjunctive therapy of myocardial ischemia, clinically applicable to a variety of cardiovascular disease adjuvant therapy. Because of its clinical use of large infusion drug, so infusion of insoluble particles in the control, will have a direct impact on product quality. Insoluble particles into the body, will cause systemic embolism and allergic and pyrogenic reactions, so to control the varieties of insoluble particles is the key to clinical drug safety. At present, in the clinical medication to prevent particles directly into the body, only by